Pediatric high-grade glioma (HGG) and pilocytic-astrocyoma/optic-pathway gliomas (PA+OPG) are each very vascular tumors but vary substantially in their treatment, clinical course and long term prognosis. In this study we demonstrate that measurements that work in adults to distinguish tumor grades (eg RCBV) cannot distinguish between pediatric HGG and PA+OPG, but a new MRI biomarker, the ratio of standardized RCBV (sRCBV) to mean diffusivity (MD) can cleanly making this distinction. This finding has significant implications for treatment management in the pediatric brain tumor population.
This abstract and the presentation materials are available to members only; a login is required.